PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial

PDS Biotechnology Corporation (NASDAQ:PDSB) unveiled compelling new data on its Versamune HPV (PDS0101) immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company’s latest abstracts reveal that patients with HPV16-positive recurrent/metastatic head and neck cancer (HNSCC) treated with PDS0101 and pembrolizumab achieved a median overall survival (mOS) of 39.3 months, more than double the previously published 15-month mOS for pembrolizumab alone. Patients with lower CPS scores also saw significant survival benefits.

A doctor holding a laptop with a digital health platform application open in front of a medical image.

The ongoing Phase 3 VERSATILE-003 trial by PDS Biotechnology Corporation (NASDAQ:PDSB), enrolling 351 patients, aims to confirm these results, with overall survival as its primary endpoint. Additionally, early findings from a Phase 2 “window of opportunity” study showed that two cycles of Versamune HPV, alone or with pembrolizumab, led to stable disease or partial response in all patients, with the combination therapy achieving a 50% reduction in circulating tumor DNA.

These results highlight Versamune HPV’s potential to set a new standard of care for HPV16-positive HNSCC, offering renewed hope for patients facing this aggressive cancer. PDS Biotechnology Corporation (NASDAQ:PDSB) will present these findings on June 2, 2025, in Chicago.

While we acknowledge the potential of PDSB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than PDSB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.